China Orphan Drug Reimbursement: Swift Action Needed – Former Genzyme GM
This article was originally published in PharmAsia News
Only 1% of 5,781 rare diseases in China have effective treatments. Facing reimbursement and infrastructure challenges, the market needs rapid action from government and industry, says Shirley Zhao, former Genzyme China general manager.
You may also be interested in...
The subsidiary of Sanofi long has pegged opening of additional plant as critical to restoring full production of Fabrazyme, which has been rationed to Fabry disease patients since a manufacturing interruption in 2009.
China's State FDA has approved Merck Serono's Kuvan (sapropterin) for orphan condition hyperphenylalaninemia in phenylketonuria or BH4 deficiency, a rare congenital metabolic disorder that increases blood phenylalanine levels. The approval underlines opportunities in the Chinese orphan drug market, says a leading Chinese expert
CanSino plans to start a Phase III study soon for its candidate with a 40,000 enrollment target, discloses its co-founder.